Karthik Nath
YOU?
Author Swipe
View article: Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks
Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks Open
Lysophosphatidic acid (LPA) signaling has emerged as a central regulatory axis in both normal physiology and disease, orchestrating diverse cellular processes such as proliferation, survival, migration, immune modulation, and tissue remode…
View article: A Study on Constipation Among Males 20-30 Age Group: A Study from Tamilnadu, India
A Study on Constipation Among Males 20-30 Age Group: A Study from Tamilnadu, India Open
Constipation is more common among males. It was assumed that men's regular consumption of junk food was a sign of their maturity. The study is being conducted at the Sree Ramakrishna Medical College of Naturopathy and Yogic Sciences and Ho…
View article: Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis Open
Whether older HLA-matched sibling donors (MSD) are preferred over younger alternative donors for allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) pr…
View article: Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma Open
Cancer Council Victora; National Health and Medical Research Council; Leukaemia Foundation; Mater Foundation.
View article: Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy Open
Chimeric Antigen Receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatmentrelated toxicity. Cytokine release syndrome and immu…
View article: Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
Intra‐tumoral and peripheral blood <span>TIGIT</span> and <span>PD</span>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma Open
In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymph…
View article: Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03 Open
Background We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. Methods Patients with ESFL …
View article: Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma Open
Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on c…
View article: Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma Open
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-ta…
View article: Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Open
View article: Prospective analysis to determine barriers to <scp>allogeneic hematopoietic cell transplantation</scp> in patients with acute leukemia
Prospective analysis to determine barriers to <span>allogeneic hematopoietic cell transplantation</span> in patients with acute leukemia Open
Allogeneic hematopoietic cell transplantation (allo‐HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo‐HCT. The primary ob…
View article: CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results Open
View article: The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies Open
View article: Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma
Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma Open
Introduction: Follicular lymphoma (FL) is the most common indolent NHL. Recently, we demonstrated in limited and advanced stage FL (LSFL, ASFL), that patients with longer remissions had raised clonally expanded intratumoral CD8+ T cells (T…
View article: RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL
RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL Open
Introduction: The TROG99.03 represents the only randomised phase III trial of combined modality therapy (CMT) in limited-stage follicular lymphoma 'LSFL', reporting a prolonged progression-free survival (PFS) in the CMT arm (MacManus, JCO,…
View article: Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma Open
A thorough understanding of the toxicities associated with CD19-directed CAR T-cell therapy will facilitate the optimal selection of patients for this therapy. Furthermore, knowledge of preventative measures of CAR T-cell related complicat…
View article: Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy Open
B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug Administration–ap…
View article: GPRC5D-Targeted CAR T Cells for Myeloma
GPRC5D-Targeted CAR T Cells for Myeloma Open
The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol Myers Squibb; ClinicalTrials.gov number, NCT04…
View article: Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma Open
View article: Activity and outcomes of autologous stem cell transplantation in the private sector in Australia
Activity and outcomes of autologous stem cell transplantation in the private sector in Australia Open
Background Few Australasian autologous stem cell transplantation (ASCT) programmes perform ASCT in the private sector. Relatively little is known about ASCT outcomes in the private sector, which varies in care delivery models to the public…
View article: A comprehensive study of the epidemiology of haematological malignancies in North Queensland
A comprehensive study of the epidemiology of haematological malignancies in North Queensland Open
Background There is an absence of clinically relevant epidemiological data in regional Australia pertaining to haematological malignancies. Aim To determine the incidence and geographical variation of haematological malignancies in North Q…
View article: Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma Open
Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility of pretherapy total metabolic tumor volume (TMTV) and maximum stan…
View article: Tumor microenvironment of follicular lymphoma
Tumor microenvironment of follicular lymphoma Open
: Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma and accounts for approximately 20% of all new non-Hodgkin lymphomas in western countries. Although FL generally has an indolent natural history, a subset can…
View article: INTRATUMORAL T‐CELLS HAVE A DIFFERENTIAL IMPACT ON FDG‐PET PARAMETERS IN FOLLICULAR LYMPHOMA
INTRATUMORAL T‐CELLS HAVE A DIFFERENTIAL IMPACT ON FDG‐PET PARAMETERS IN FOLLICULAR LYMPHOMA Open
Introduction: Results of the prognostic impact of the pre-therapy FDG-PET parameters TMTV (3D tumor burden of all involved sites) and SUVmax (highest FDG-uptake within a single lesion) in follicular lymphoma (FL) are conflicting and appear…
View article: Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas
Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas Open
Over the past decade therapies targeting the PD-1 axis with monoclonal antibodies to reinstate host immune function have revolutionized the clinical management of some cancers but have had minimal impact on others. This dichotomy is exempl…
View article: Targeted Treatment of Follicular Lymphoma
Targeted Treatment of Follicular Lymphoma Open
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, parti…
View article: Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy
Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy Open
Objectives A diverse intratumoral T‐cell receptor (TCR) repertoire is associated with improved survival in diffuse large B‐cell lymphoma (DLBCL) treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimm…
View article: Perioperative Risk Assessment and Communication
Perioperative Risk Assessment and Communication Open
View article: Issue Information
Issue Information Open
View article: Big data: creating the right balance
Big data: creating the right balance Open